Psyched Wellness (CSE:PSYC, OTCQB:PSYCF) Ltd CEO Jeff Stevens tells Proactive the group has revealed the path to market for its lead product AME-1, an Amanita Muscaria extract.
Stevens says that the AME-1 derived consumer products will be available in US stores in the second quarter of 2022. Psyched is now in the midst of a self-Generally Recognized As Safe dossier review of AME-1 by an external panel of experts, which permits substances to be exempt from pre-market review by the FDA.